Sanofi, GSK begin clinical trial for COVID-19 vaccine

By The Science Advisory Board staff writers

September 3, 2020 -- Sanofi and GlaxoSmithKline (GSK) have started the phase I/II clinical trial for an adjuvanted recombinant protein-based COVID-19 vaccine candidate.

The study is a randomized, double-blind, and placebo-controlled trial designed to evaluate the safety, tolerability, and immunogenicity of the candidate. A total of 440 healthy adults are being enrolled in the trial across 11 sites in the U.S.

The companies anticipate results as early as December, which will support the initiation of a phase III trial expected to begin in December as well. With sufficient data, the companies plan to request regulatory approval in the first half of 2021.

Preclinical data showed that the vaccine candidate produced high levels of neutralizing antibodies after two injections of the adjuvanted recombinant vaccine that was comparable to levels in humans who recovered from COVID-19. Plans to publish the preclinical results are in the works for later in the year.

Sanofi is leading the clinical development and registration of the COVID-19 vaccine. In parallel, both companies are scaling up manufacturing of the antigen and adjuvant with the goal of producing one billion doses in 2021.

The development of the vaccine candidate is being supported through funding and collaboration with the Biomedical Advanced Research and Development Authority, a U.S. federal agency.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here